PH12020500045A1 - Novel composition of enzalutamide oral dosage form and method of manufacturing thereof - Google Patents
Novel composition of enzalutamide oral dosage form and method of manufacturing thereofInfo
- Publication number
- PH12020500045A1 PH12020500045A1 PH12020500045A PH12020500045A PH12020500045A1 PH 12020500045 A1 PH12020500045 A1 PH 12020500045A1 PH 12020500045 A PH12020500045 A PH 12020500045A PH 12020500045 A PH12020500045 A PH 12020500045A PH 12020500045 A1 PH12020500045 A1 PH 12020500045A1
- Authority
- PH
- Philippines
- Prior art keywords
- enzalutamide
- manufacturing
- dosage form
- oral dosage
- novel composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel composition of oral dosage forms of enzalutamide with pharmaceutically acceptable excipients and method of manufacturing thereof. The invention provides economical and advanced dosage form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721023465 | 2017-07-04 | ||
PCT/IB2017/057273 WO2019008426A1 (en) | 2017-07-04 | 2017-11-21 | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12020500045A1 true PH12020500045A1 (en) | 2020-11-09 |
Family
ID=64950639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12020500045A PH12020500045A1 (en) | 2017-07-04 | 2020-01-03 | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof |
Country Status (7)
Country | Link |
---|---|
BR (1) | BR112020000207A2 (en) |
CL (1) | CL2020000017A1 (en) |
MX (1) | MX2020000213A (en) |
PH (1) | PH12020500045A1 (en) |
RU (1) | RU2020105102A (en) |
WO (1) | WO2019008426A1 (en) |
ZA (1) | ZA202000609B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR118925A1 (en) * | 2020-05-13 | 2021-11-10 | Novocap S A | CONCENTRATED LIQUID SOLUTION OF NON-STEROID ANTIANDROGENS AND PROCEDURE FOR PREPARING THE SOLUTION |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200015830A (en) * | 2014-02-05 | 2020-02-12 | 레크 파마슈티칼스 디.디. | Solid pharmaceutical compositions of androgen receptor antagonists |
-
2017
- 2017-11-21 RU RU2020105102A patent/RU2020105102A/en unknown
- 2017-11-21 BR BR112020000207-0A patent/BR112020000207A2/en unknown
- 2017-11-21 WO PCT/IB2017/057273 patent/WO2019008426A1/en active Application Filing
- 2017-11-21 MX MX2020000213A patent/MX2020000213A/en unknown
-
2020
- 2020-01-03 CL CL2020000017A patent/CL2020000017A1/en unknown
- 2020-01-03 PH PH12020500045A patent/PH12020500045A1/en unknown
- 2020-01-29 ZA ZA2020/00609A patent/ZA202000609B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2020000213A (en) | 2020-08-17 |
ZA202000609B (en) | 2021-08-25 |
RU2020105102A (en) | 2021-08-04 |
BR112020000207A2 (en) | 2020-07-07 |
CL2020000017A1 (en) | 2020-05-22 |
WO2019008426A1 (en) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018007704A (en) | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant. | |
SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
MX2015010921A (en) | Carbazole compounds useful as bromodomain inhibitors. | |
EA201690962A1 (en) | COMPOSITIONS | |
EP3705118A4 (en) | Oral solid dosage form composition having improved disintegration and preparation method therefor | |
TR201821116A2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND THE MANUFACTURING METHOD | |
MX2017008386A (en) | Site specific dosing of a btk inhibitor. | |
IN2013MU03583A (en) | ||
SG10201902203VA (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
IN2014MU00303A (en) | ||
PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
MX2017015137A (en) | Once daily oral pharmaceutical composition of isotretinoin. | |
MX2018012618A (en) | Oral pharmaceutical compositions of mesalazine. | |
EA201791009A1 (en) | COMPOSITIONS CONTAINING CYCLOSPORIN | |
MX2021002322A (en) | Novel methods. | |
CR20210158A (en) | Vitamin d pediatric dosage forms, methods of making and using | |
MX2019001634A (en) | Amide compounds, pharmaceutical compositions thereof, and methods of using the same. | |
MX2021003862A (en) | Crystalline forms and processes of lenvatinib besylate. | |
TR201721505A2 (en) | The combination comprising linagliptin and metformin | |
MX2015000179A (en) | Itraconazole compositions and dosage forms, and methods of using the same. | |
MX2017008983A (en) | Sulfonamide pharmaceutical composition. | |
TR201722603A2 (en) | Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion | |
PH12020500045A1 (en) | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof |